Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419677 | 0.90 | MAPT (0.50) | MAPTMEN1KMT2ACYP19A1CYP11B1 | |
| SCHEMBL31440585 | 0.90 | MAPT (0.53) | MAPTMEN1KMT2ACYP19A1CYP1A2 | |
| SCHEMBL30466057 | 0.84 | MAPT (0.51) | MAPTMEN1KMT2ACYP19A1CYP11B1 | |
| SCHEMBL4659661 | 0.84 | MAPT (0.51) | MAPTMEN1KMT2ACYP19A1CYP11B1 | |
| SCHEMBL21910024 | 0.78 | PTGES (0.45) | MAPTMEN1KMT2ACYP19A1PTGES | |
| SCHEMBL21908834 | 0.78 | PTGES (0.48) | MAPTMEN1KMT2ACYP19A1PTGES | |
| SCHEMBL15729343 | 0.78 | KDM1A (0.46) | MAPTMEN1KMT2ALMNA | |
| SCHEMBL9388459 | 0.77 | MEN1 (0.58) | MAPTMEN1KMT2ACYP19A1CYP11B1 | |
| SCHEMBL21071296 | 0.76 | HTR1A (0.55) | MAPTMEN1KMT2ACYP19A1CRHBP | |
| SCHEMBL8808139 | 0.76 | MEN1 (0.69) | MAPTMEN1KMT2ACYP19A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448492-B1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12404242-B2 | Compositions and methods for making and using small molecules in the treatment of cancer | REGLAGENE, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250109105-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE, INC. | 2025-04-03 | — | — | US | disclosed |
| EP-4448492-A1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | Reglagene, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023111996-A1 | COMPOSITIONS AND METHODS OF MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | REGLAGENE HOLDING, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109105-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES IN THE TREATMENT OF CANCER | CD47, RB1, TP53 | MAPT 4104/4885MEN1 160/4885KMT2A 700/4885 |
| US-12404242-B2 | Compositions and methods for making and using small molecules in the treatment of cancer | CD47, RB1, TP53 | MAPT 4104/4885MEN1 160/4885KMT2A 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.